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enzyme, is associated with substrate‐specific altered clearance of multiple drugs.
CYP2B6 is a minor contributor to hepatic nicotine metabolism, but the enzyme has
been proposed as relevant to nicotine‐related behaviors because of reported
CYP2B6 mRNA expression in human brain tissue. Therefore, we hypothesized that
CYP2B6 variants would be associated with altered nicotine oxidation, and that nicotine metabolism by CYP2B6 would be detected in human brain microsomes. We
generated recombinant enzymes in insect cells corresponding to nine common
CYP2B6 haplotypes and demonstrate genetically determined differences in nicotine
oxidation to nicotine iminium ion and nornicotine for both (S) and (R)‐nicotine.
Notably, the CYP2B6.6 and CYP2B6.9 variants demonstrated lower intrinsic clearance relative to the reference enzyme, CYP2B6.1. In the presence of human brain
microsomes, along with nicotine‐N‐oxidation, we also detect nicotine oxidation to
nicotine iminium ion. However, unlike N‐oxidation, this activity is NADPH independent, does not follow Michaelis‐Menten kinetics, and is not inhibited by NADP or
carbon monoxide. Furthermore, metabolism of common CYP2B6 probe substrates,
methadone and ketamine, is not detected in the presence of brain microsomes. We
conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6
variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6
activity in human brain.
KEYWORDS
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1 | INTRODUCTION

nicotine to nicotine iminium ion and subsequently to cotinine by
CYP2A6, one of three nicotine metabolism pathways (Figure 1). Vari-

Tobacco consumption and liability to nicotine dependence are heri1,2

table traits.

One clearly implicated pathway is the C‐oxidation of

ation in nicotine C‐oxidation influences cigarette consumption
among dependent smokers and consequent disease risk. CYP2A6 is
responsible for 70%‐80% of nicotine metabolism in most people,3
and the mechanism of influence is straightforward: smokers with

Abbreviations: CLint, intrinsic clearance; CYP, cytochrome P450; FMO, flavin-containing

reduced CYP2A6 function metabolize nicotine more slowly, delaying

monooxygenase; HBM, human brain microsomes; NADPH, nicotinamide
dinucleotide phosphate; POR, P450 oxidoreductase; Vmax, maximum velocity.

the onset of the withdrawal symptoms that compel nicotine addicts

adenine
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to reach for the next cigarette. Hence, polymorphisms in CYP2A6

described.17,21 Haplotype selection was based on the known clinical

causing slower nicotine metabolism are also associated with reduced

significance and frequency of the polymorphism, and a desire to

cigarette consumption and disease risk in multiple populations.4-7

inform the mechanistic basis for the influence of these polymor-

Nicotine is also metabolized via two other major pathways: glu-

phisms on metabolism. There is growing evidence that the influence

curonidation by UGT2B10, and oxidation to nicotine‐N‐oxide by the

of CYP2B6 polymorphisms varies between substrates, and may vary

flavin‐containing monooxygenases (FMOs). Variation in FMO3 is

between enantiomers of those substrates. For example, 516G>T

associated with altered hepatic nicotine metabolism.8

(Q172H) is a canonical single nucleotide polymorphism (SNP)

CYP2B6 is a minor contributor to hepatic nicotine metabolism

thought to result in diminished metabolism,17,21,22 while 785A>G

9

with a Km approximately 10‐fold higher than that of CYP2A6.

(K262R) alone causes increased activity for some but not all 2B6

Genetic variation in the CYP2B6 locus has a small but clinically

substrates.21,23 To evaluate contribution from the two major SNPs,

insignificant influence on in vivo nicotine clearance in most sub-

we selected variants with various combinations of these mutations

10,11

but may be important in CYP2A6 slow metabolizers.

(2B6*4, *6, *7, *9, *16, *19, *26) even though some are minor in pop-

CYP2B6 has also been reported to be expressed in human brain tis-

ulation frequency. The other three 2B6 variants (*5, *17, *18) have

sue,12 unlike CYP2A6, and it has therefore been proposed that

relatively high allele frequency.

jects,

genetic variation affecting the CYP2B6 enzyme might play a signifi-

Human brain microsomes were prepared as described8 from de‐

cant role in nicotine‐related phenotypes.13 CYP2B6 is highly poly-

identified cerebral cortex flash‐frozen postmortem obtained from the

morphic, and common haplotypes, especially CYP2B6*6 and *9,

National Disease Research Interchange (NDRI), Philadelphia PA, USA.

containing 516G>T (Q172H, minor allele frequency 26% in Euro-

They included four Caucasian males, one Caucasian female, and one

pean Americans, 37% in African Americans (http://evs.gs.washing

African American male with ages ranging from 58 to 90 years. None

ton.edu/EVS/)) are associated with clinically significantly altered

were reported to be current smokers or substance abusers. In brief,

pharmacokinetics for different substrates, relative to the reference

tissues were homogenized with a glass‐teflon homogenizer in ice‐

allele.14-19 Because the effects of CYP2B6 polymorphisms on

cold potassium phosphate buffer pH 7.4, and centrifuged 20 minute

CYP2B6 activity is substrate‐specific, activities of different CYP2B6

at 9000g. The S9 fraction was centrifuged 60 minute at 100 000g to

isoforms cannot be assumed for untested substrates, such as nico-

obtain a microsomal pellet which was resuspended, further homoge-

tine. Therefore, we have expressed polymorphic CYP2B6 enzymes

nized, centrifuged, and resuspended in buffer containing 20% glyc-

and measured their nicotine metabolism activity in vitro. We further

erol24,25 for storage at −80°C. Total brain protein concentrations

attempted to measure cytochrome P450‐mediated nicotine metabo-

were determined using Bio‐Rad Protein Assay Dye Regent Concen-

lism in human brain microsomes, where FMO activity was previously

trate which is based on Bradford method. Results were expressed as

8,20

demonstrated,

using nicotine and other CYP2B6 probe sub-

fmol min−1 mg−1 of total brain protein, as CYP2B6 protein was not

strates.

detectable.

2 | MATERIALS AND METHODS

2.1 | Cytochrome P450 and b5 concentration and
POR activity determination

CYP2B6 variants, reference allele P450 oxidoreductase (POR), and

All assays for P450 content, b5 content, and POR activity were car-

reference allele cytochrome b5 vectors were previously generated,

ried out using a Synergy MX Microplate Reader (Biotek, Winooski,

and recombinant proteins previously expressed in insect cells, as

VT). Total protein concentrations were determined using Bio‐Rad

FIGURE 1
pathways

Nicotine metabolism
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Protein Assay Dye Regent Concentrate which is based on Bradford

75% B until 5.0 minutes, immediately decreased back to 25% B and

method. P450 concentration was determined by difference spectrum

re‐equilibrated at initial conditions for 3.0 minutes.

of ferrous‐carbon monoxide complex in a CO binding assay (reduced

Ketamine incubations were performed with 80 μmol L−1 keta-

vs reduced CO) using an extinction coefficient De450-490 nm of

mine, and processed and analyzed as previously described17 In brief,

−1

91 mmol L

−1

cm . Cytochrome b5 content was determined by dif-

the reactions were quenched with 20% trichloroacetic acid

ference spectrum of NADH‐reduced and oxidized b5 using an extinc-

containing norketamine‐d4. The plate was centrifuged at 900 g for

tion coefficient De424-410 nm of 185 m mol L−1 cm−1.

5 minutes and the supernatant was subjected to solid phase extrac-

P450 oxidoreductase activity was measured by NADPH‐cyto-

tion.30 Analytes were eluted with methanol and evaporated to dry-

chrome c reductase activity. To 200 μL of diluted cell lysate in

ness under nitrogen. For analysis, samples were resuspended in

0.3 mol L−1 potassium phosphate buffer at pH 7.7 containing

mobile phase (10 mmol L−1 ammonium acetate, pH 7.6). High perfor-

40 μmol L

−1

−1

cytochrome c, 100 μmol L

NADPH was added to ini-

mance liquid chromatography (HPLC)‐mass spectrometry analysis

tiate the reduction of cytochrome c and the reaction was followed

was performed on an ultra‐fast liquid chromatography system

at 550 nm and 23°C. The reaction rate was calculated using an

(Shimadzu Scientific Instruments, Columbia, MD) with a CMB‐20A

extinction coefficient of e550 nm of 21 mmol L−1 cm−1 for reduced

system controller, two LC‐20ADXR pumps, DGU‐20A3 degasser,

cytochrome c. POR activity was converted to POR content based on

SIL‐20AC autosampler, FCV‐11AL solvent selection module, and

the assumption that 3000 nmol of cytochrome c is reduced/min per

CTO‐20A column oven (30°C) containing a ChiralPak AGP analytical

nmol POR at 23°C.17,26

column (100 × 2.0 mm, 5 μm) and AGP guard column (10 × 2.0 mm)
(Chiral Technologies, West Chester, PA), coupled to an API 4000
QTrap LC‐MS/MS linear ion trap triple quadrupole tandem mass

2.2 | Substrate metabolism

spectrometer (Applied Biosystems/MDS Sciex, Foster City, CA). The

All incubations were carried out in 96‐well PCR plates in 50 μL
total volume at 37°C, as previously described.

8

mobile phase (0.22 mL min−1) was 10 mmol L−1 ammonium acetate

Incubations with

in water, pH 7.60 (A) and isopropanol (B). The column was equili-

recombinant CYP2B6/POR/b5 proceeded for 10 minutes and incu-

brated with 4% B, maintained after injection for 0.1 minute, then a

bations with human brain microsomes proceeded for 1 hour, unless

linear gradient to 16.8% B applied over 12 minutes, and then

otherwise noted, following a 2‐minute preincubation and initiation

reverted back to 4% B over 0.5 minute and re‐equilibrated for

with 25, 50, 100, 250, 500, 1000, 1,500, or 2,000 μmol L−1 S‐nico-

3.5 minutes.

tine or R‐nicotine (Toronto Research Chemicals, Toronto, Canada)
in the presence of 1 mmol L−1 NADPH (Sigma‐Aldrich, St. Louis,
MO). Inhibition of metabolite formation was tested at 100 μmol
L−1 nicotine for convenience to ensure metabolite concentrations

2.3 | Liquid chromatography tandem mass
spectrometry of nicotine metabolites

remained within the concentration curve after incubation of up to

Nicotine metabolites were analyzed by liquid chromatography tan-

6 hours. Reactions were quenched by adding 10 μL 15% zinc sul-

dem mass spectrometry (LC‐MS\MS) based on previous methods8

fate containing 200 ng mL−1 of the internal standard, (d3)‐nicotine‐

and quantified using the ratio of metabolite to internal standard,

N‐oxide (Toronto Research Chemicals, Toronto, Canada). Samples

subtracting background from control incubations (without NADPH),

were centrifuged and supernatants were removed for LC/MS

and using calibration curves. The subtraction of control (NADPH‐)

analysis.

incubations was necessary to subtract trace nicotine metabolites

Methadone incubations were performed with 10 μmol L

−1

present in the substrate, nicotine. Three replicates were performed

methadone and processed and analyzed as previously described.21,27

for each incubation. Further control incubations for brain micro-

In brief, methadone was from the National Institute on Drug Abuse

somes included with boiled protein or without protein.

(Bethesda, MD); all other reagents were purchased from Sigma‐

Liquid chromatography tandem mass spectrometry analyses were

Aldrich. Reactions were quenched with 40 μl 20% trichloroacetic

performed on an API 4000 Q‐TRAP triple quadrupole mass spec-

acid containing internal standard (d3‐EDDP), and centrifuged for

trometer (Applied Biosystems Sciex, Foster City, CA) equipped with

5 minutes at 2500g; the supernatant was processed by solid phase

an electrospray source. The HPLC system consisted of two LC 20AC

extraction as previously described,28,29 except that for Strata‐X‐C

pumps with a CTO‐20A column oven, SIL‐20A autosampler, DGU‐

33‐μm, 30 mg/well plates (Phenomenex, Torrance, CA) were used.

20A3 degasser, FCF‐11AL valve, and a CBM 20A controller (Shi-

Analysis was performed on a Sunfire C18 column (2.1 × 50 mm,

madzu, Columbia, MD). The chromatographic separation was per-

3.5‐μm) (Waters, Milford, MA) with a 2‐μm column filter guard

formed on an xBridge column (150 × 2.1, 3.5 μm, Waters, Milford,

(Supleco Analytical, Bellefonte, PA). Sample injections were 25 μL

MA) with an inline precolumn 0.2 μm filter. The injection volume

and the column oven was held at 30°C. Mobile phase A was

was 5 μL and the oven temperature was 40°C. Mobile phase (0.3 mL

4.5 mmol L

−1

ammonium acetate in Milli‐Q water, pH 4.5, and

mobile phase B was 4.5 mol L

−1

ammonium acetate in acetonitrile.
−1

min−1) was (A) 4.5 mmol L−1 ammonium acetate pH 4.0 and (B)
4.5 mmol L−1 ammonium acetate in acetonitrile using the following

The mobile phase gradient (0.4 mL min ) was 25% B for 0.5 min-

program: 1% B for 4 minutes, linear gradient to 25% B between 4

utes, linear gradient to 75% B between 0.5 and 4.2 minutes, held at

and 5 minutes, held at 25% B until 6.0 minutes, and then

|
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re‐equilibrated to initial conditions between 6.5 and 8.5 minutes.

min−1 nmol−1) and nornicotine (Clint = 0.5 vs 1.0 μL min−1 nmol−1)

Under these conditions, the retention times for nicotine iminium and

(Figure 2).

nornicotine (a minor CYP2B6 nicotine metabolite9) were 2.5 and

Variation in CYP2B6 affects enzyme activity differently depend-

3.7 minutes, respectively; for cis and trans nicotine‐N‐oxide, they

ing on substrate, which may include differences between isomers of

were 4.7 and 5.2 minutes, respectively. The instrument was operated

the same molecule. Nicotine occurs in two isomers, though approxi-

in positive‐ion mode at 450°C with an ion spray voltage of 5500 V,

mately 99% of naturally occurring nicotine derived from tobacco and

entrance potential of 10 V, and exit potential of 22 V. The curtain

other plants is the (S) isomer. In order to determine if effects on

gas was set at 20, ion source gas 1 at 30, and ion source gas 2 at

CYP2B6 nicotine metabolism activity were also enantiomer‐specific,

40. Transitions monitored for nicotine iminium were m/z 161 → 130,

incubations with four CYP2B6 haplotypes were repeated with (R)‐

for

nornicotine,

179 → 132,

m/z

and

149 → 117,

for

nicotine‐N‐oxide

m/z

nicotine (Table 2). Km and Vmax parameters were different for (R)‐

(d3)‐nicotine‐N‐oxide,

m/z

nicotine and (S)‐nicotine, but differences between CYP2B6 variants

for

deuterated

182 → 132.

appear consistent, that is, the activity of CYP2B6.6, was again lower
than the reference allele enzyme for nicotine iminum (Clint = 0.8 vs
1.8 μL−1 min−1 nmol−1) and nornicotine (Clint = 0.1 vs 0.2 μL−1

2.4 | Statistical analysis

min−1 nmol−1). Interestingly, the regioselectivity of the enzyme, that

Michaelis‐Menten parameters for recombinant enzyme experiments

is, the metabolite ratio of nicotine iminium ion vs nornicotine, was

were determined by nonlinear regression using SigmaPlot (Systat

relatively consistent among different CYP2B6 variants, but differed

Software, San Jose, CA).

between (S)‐ and (R)‐nicotine (Tables 1 and 2).

3 | RESULTS

3.2 | CYP2B6 substrate metabolism by human brain
microsomes

3.1 | Nicotine oxidation by variant recombinant
CYP2B6 enzymes

Microsomes were prepared from the cerebral cortices of six post-

Nine recombinant versions of the CYP2B6 enzymes, representing

as a positive control for tissue quality because FMO enzyme activity

common CYP2B6 haplotypes, were expressed to assess their relative

is diminished by heat treatment at room temperature or repeated

nicotine metabolism activities. Two nicotine metabolites were mea-

freeze‐thawing. Nicotine‐iminium, but not nornicotine, was detected

sured, nicotine iminium ion and nornicotine, with Km and Vmax

in incubations with all six samples. In the presence of 100 μmol L−1

parameters determined for both metabolites for each variant

nicotine, the average turnover was 264 ± 133 (range 142‐498) fmol

(Table 1). Our results confirm the role of CYP2B6 in nornicotine for-

min−1 mg−1 of microsomal protein. Activity was not significantly cor-

9

mortem individuals. Nicotine‐N‐oxidation by FMO enzymes was used

As expected, the activity of the most common variant

related with age (mean 72.9 ± 11.6 years) or postmortem interval

enzyme, CYP2B6.6, was lower than the reference allele enzyme,

(mean 11.6 ± 3.1 hours). The activity remained linear for at least

CYP2B6.1, regarding both nicotine iminum (Clint = 1.9 vs 3.2 μL

6 hours (Figure 3). Incubation conditions were interrogated to

mation.

T A B L E 1 Kinetic parameters for (S)‐nicotine‐iminium and (S)‐nornicotine formation by variant CYP2B6 proteins
(S)‐iminium

Allele

Protein variant

*1

(S)‐nornicotine

Km
(μmol L−1)

Vmax
(pmol min−1
pmol−1)

CLint
(mL−1 min−1
nmol−1)

Km
(μmol L−1)

Vmax
(pmol min−1
pmol−1)

CLint
(mL min−1
nmol−1)

CLint
(nornicotine/iminium)

269 ± 37

0.85 ± 0.04

0.0032

184 ± 27

0.19 ± 0.01

0.0010

0.33

333 ± 32

0.83 ± 0.03

0.0025

167 ± 28

0.21 ± 0.01

0.0013

0.50

*4

K262R

*5

R487C

257 ± 22

0.66 ± 0.01

0.0026

132 ± 18

0.09 ± 0.00

0.0007

0.27

*6

Q172H/K262R

307 ± 16

0.58 ± 0.01

0.0019

110 ± 15

0.06 ± 0.00

0.0005

0.29

*7

Q172H/K262R/
R487C

236 ± 21

0.56 ± 0.01

0.0024

108 ± 23

0.09 ± 0.00

0.0008

0.35

*9

Q172H

406 ± 44

0.18 ± 0.01

0.0004

134 ± 21

0.02 ± 0.00

0.0001

0.34

*17

T26S/D28G/R29T

332 ± 22

0.85 ± 0.02

0.0026

130 ± 17

0.11 ± 0.00

0.0008

0.33

*19

Q172H/K262R/
R336C

271 ± 27

0.60 ± 0.02

0.0022

114 ± 26

0.06 ± 0.00

0.0005

0.24

*26

P167A/Q172H/
K262R

189 ± 21

0.41 ± 0.01

0.0022

86 ± 20

0.08 ± 0.00

0.0009

0.43
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substrate. Here, we demonstrate how these common variants also

nicotine iminium
nornicotine

affect nicotine metabolism in vitro. The differences we report, both

0.0020

activities for common variants including CYP2B6.6 and CYP2B6.9,
relative to the reference allele enzyme, CYP2B6.1. Because (S)‐nico-

0.0010

tine is the common naturally occurring form of nicotine relevant to

0.0000

ml/min/nmol

for (S)‐nicotine and (R)‐nicotine, confirm the expectation of altered

smoking behavior, experiments with (R)‐nicotine were only performed to explore substrate specificity and stereoselectivity. The
activities of the nine enzyme variants also differed with regard to
*1

*4

*5

*6

*7

*9

*17

*19

*26

CYP2B6 variants

the relative metabolite ratios of (S)‐nicotine iminium and (S)‐nornicotine. The differences in this ratio demonstrate altered regioselectivity
associated with each polymorphism, that is, changes in the activity

F I G U R E 2 Intrinsic clearance (CLint) of (S)‐nicotine to nicotine
iminium ion and nornicotine by variant recombinant CYP2B6
enzymes

of each enzyme isoform depend on which region of the substrate

determine whether iminium production was consistent with cyto-

two amino acid changes, Q172H and K262R, which individually

chrome P450 activity. The activity was abolished by heat‐treatment

define the CYP2B6*9 and CYP2B6*4 variants respectively, and

(65°C 1 hour), but did not require NADPH, and was not inhibited by

together define the very common CYP2B6*6 haplotype. For most

NADP (2 mmol L−1) or carbon monoxide treatment. Nicotine‐N‐

substrates, activity of the CYP2B6.9 variant is exceptionally low,

oxide, the product of FMO enzymes (Figure 1), was also detected in

activity of the CYP2B6.4 variant is similar or greater than that of the

the microsome incubations, but its formation required NADPH. On

reference allele, while the activity of CYP2B6.6 lies between

further characterizing one brain, we found the NADPH‐independent

CYP2B6.4 and CYP2B6.9, depending on substrate.14,21,22 This

molecule the enzyme oxidizes,35 resulting in the formation of nicotine iminum vs nornicotine.
Of particular interest are the differences in activity related to the

nicotine‐iminium formation did not follow Michaelis‐Menten kinetics

demonstrates that the K262R amino acid change can partially com-

(Figure 4). Cotinine and hydroxycotinine were also not generated in

pensate for the Q172H loss‐of‐function, depending on substrate,

any human brain incubation.

and we find this to be the case for nicotine as well. CYP2B6*6 is the

To further investigate possible CYP2B6 activity in human brain

most commonly studied variant haplotype because of its high popu-

microsomes, we incubated them with two additional common

lation frequency and has been associated with low activity

CYP2B6 probe substrates, methadone (10 μmol L−1) and ketamine

in vivo.16,33 However, it is also important to note that part of this

−1

(80 μmol L ), the approximate Km for CYP2B6 for each sub-

loss of activity may be due to differences in mRNA or protein

strate.27,31 Neither 2‐ethylidene‐1,5‐dimethyl‐3,3‐diphenylpyrrolidine

expression or splicing, and not strictly related to catalytic activ-

(EDDP) nor norketamine were detected, respectively.

ity.10,36,37 CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism.34
We previously demonstrated that common CYP2B6 haplotypes,

4 | DISCUSSION

including missense variants and noncoding variants that affect gene
splicing, are associated with differences in in vivo nicotine metabo-

Extensive evidence demonstrates that functional variation in cyto-

lism.10 However, the small contribution of CYP2B6 to hepatic nico-

chrome P450 genes can significantly affect the metabolism of many

tine metabolism38 is unlikely to influence smoking behaviors.

small molecules including pharmaceuticals and toxins. Importantly,

CYP2B6 mRNA expression has been reported in human brain,12

common functional polymorphisms in CYP2B6 alter enzyme activity

although direct evidence of CYP2B6 activity in brain tissue was not

in a substrate‐dependent manner,15,16,19,22,23,32-34 and thus it is

previously demonstrated. It has therefore been suggested that

important to evaluate these enzyme variants for any CYP2B6

genetically determined variation in CYP2B6 activity in extrahepatic

T A B L E 2 Kinetic parameters for (R)‐nicotine‐iminium and (R)‐nornicotine formation by variant CYP2B6 proteins
(R)‐iminium

Allele

Protein variant

*1
*4

K262R

*6

Q172H/K262R

*9

Q172H

(R)‐nornicotine

Km (μmol L−1)

Vmax
(pmol min−1
pmol−1)

CLint
(mL min−1
nmol−1)

Km (μmol L−1)

Vmax
(pmol min−1
pmol−1)

CLint (mL min−1
nmol−1)

CLint
(nornicotine/iminium)

1537 ± 352

2.78 ± 0.24

1602 ± 436

2.11 ± 0.32

0.0018

1288 ± 289

0.25 ± 0.03

0.0002

0.11

0.0013

936 ± 314

0.15 ± 0.02

0.0002

0.11

918 ± 409

0.73 ± 0.15

5040 ± 2276

0.72 ± 0.25

0.0008

956 ± 584

0.07 ± 0.02

0.0001

0.10

0.0001

1435 ± 665

0.03 ± 0.01

0.0000

0.13
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the mechanism of this weak activity was obscure. It is independent of
the cofactor NADPH and not inhibited by either carbon monoxide or
NADP, though the activity was abolished by heat treatment of the

15

microsomes. Meanwhile, the production of nicotine‐N‐oxide in the
same incubations required NADPH and was inhibited by carbon
monoxide, NADP, and heat treatment, as expected. We therefore conP450s or any typical enzymatic activity. NADP and carbon monoxide

10

pmol/mg

clude that the iminium ion detected was not due to cytochrome
are general inhibitors of CYP enzymes. Had either general inhibitor
abolished the activity, we would have pursued other specific inhibitors

5

to narrow down the source of the activity to specific enzymes. Given
the high Km of CYP2B6 for nicotine, we further probed human brain

HBMs
HBMs + NADPH
HBMs + NADP
HBMs + CO

microsomes with two common CYP2B6 substrates, ketamine and
methadone, and found no evidence of metabolism of either.

0

Variation in local nicotine metabolism in the brain is ultimately
interesting because of the potential for targeting these pathways to

0

1

2

3
hrs

4

5

6

aid smoking cessation. Our prior work suggested that differences in
nicotine metabolism within the brain might influence nicotine depen-

F I G U R E 3 Nicotine iminum formation over time in the presence
of human brain microsomes (HBMs), with and without NADPH,
inhibited by NADP or following carbon monoxide (CO) treatment

dence in ways qualitatively different from the influence of hepatic
metabolism; namely, common functional variation in an enzyme
active in both liver and brain, FMO3, is associated with a significant
difference in nicotine dependence independent of cigarette consump-

Human Brain Microsome nicotine-iminium formation

tion level. Meanwhile, variation in the primary cytochrome‐P450‐

0.6

mediated nicotine metabolism pathway affects consumption among
dependent smokers but not liability to become dependent.8,39 It was

0.4

of these two pathways are related to inherent differences in their
activities—that is, the metabolites produced—or differences in their

0.3

tissue distributions. If the highly polymorphic CYP enzymes responsible for nicotine C‐oxidation were active in brain, it would argue
against FMO3's local brain activity being the mechanism of its

0.2

fmol/mg/min

0.5

therefore important to understand whether the divergent influences

0.1

unique influence on dependence. Unlike CYP2A6, CYP2B6 mRNA
expression has been reported in human brain tissue, but aside from

0.0

its role in bupropion metabolism, genetic variation in CYP2B6 has

500

1000

1500

2000

µM Nicotine
F I G U R E 4 Nicotine iminum ion formed per mg human brain
microsomal protein per minute

not been associated with smoking phenotypes. However, given the
well‐documented substrate specificity of functional variation in
CYP2B6, it was also necessary to determine which variants affect
nicotine metabolism, a question not previously addressed in vitro. A
key limitation of our study was the problem of enzymatic stability in
postmortem brain tissue. Nevertheless, if undetected CYP2B6 activ-

tissues might influence smoking behavior by altering local nicotine
13

levels in the brain.

ity does occur in the human brain, with the potential to influence

We recently demonstrated nicotine‐N‐oxidation

smoking behavior in a similar manner to FMO3, associations

by flavin‐containing monoxygenases in microsomes prepared from

between CYP2B6 genotype and nicotine dependence should be

human brain.8 This provided an opportunity to further investigate

detectable in human genetic studies based on our in vitro activity

possible cytochrome P450‐related nicotine metabolism in post-

results together with previously published findings regarding varia-

mortem samples known to retain detectable microsomal enzyme

tion in CYP2B6 expression.

activity. Given the difficulty of obtaining postmortem human brain

In summary, we conclude that nicotine metabolism by CYP2B6 is

material, it was important to have a positive control for tissue qual-

stereoselective, and common polymorphisms in CYP2B6 significantly

ity. Postmortem intervals before initial freezing were typically

influence the oxidation of both (S) and (R)‐nicotine to nicotine imi-

12 hours or more, and FMO activity is also subject to degradation at

nium and nornicotine. However, the small contribution of CYP2B6

room temperature and following repeated freeze‐thawing.

to nicotine metabolism in the liver, and its undetectable activity in

Interestingly, we found nicotine iminium ion produced in the presence of human brain microsomes (nornicotine was not detected), but

human brain tissue, make it highly unlikely that this genetic variation
influences complex smoking behaviors.
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